Control of pro-angiogenic cytokine mRNA half-life in cancer: The role of AU-rich elements and associated proteins

Journal of Interferon and Cytokine Research

Volumn 34, Issue 4, 2014, Pages 242-254

  Griseri, Paola ^a   Pagès, Gilles ^b  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF NICE SOPHIA ANTIPOLIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AU RICH RNA BINDING PROTEIN; BINDING PROTEIN; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GELATINASE A; GELATINASE B; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; POLYADENYLATE BINDING PROTEIN INTERACTING PROTEIN 2; RNA BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN; ANGIOGENIC FACTOR; TUMOR MARKER;

3' UNTRANSLATED REGION; ANGIOGENESIS; AU RICH ELEMENT; AUTOIMMUNITY; BREAST CANCER; BREAST TUMOR; CARCINOGENESIS; COLON CANCER; CYTOKINE RELEASE; GENE CONTROL; GLIOMA; HALF LIFE TIME; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG TUMOR; NEOPLASM; NONHUMAN; OVARY TUMOR; POLYARTHRITIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN SYNTHESIS; REVIEW; TANDEM REPEAT; THYROID TUMOR; UTERUS TUMOR; ZINC FINGER MOTIF; ANIMAL; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); RNA STABILITY; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; AU RICH ELEMENTS; CYTOKINES; HALF-LIFE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RNA STABILITY; RNA, MESSENGER; RNA-BINDING PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84898736765     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0140     Document Type: Review

References (157)

1. Abdelmohsen K, Gorospe M. 2010. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1(2):214-229.
2. Al-Ahmadi W, Al-Ghamdi M, Al-Souhibani N, Khabar KS. 2013. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J Pathol 230(1):28-38.
3. Anant S, Houchen CW. 2009. HuR and TTP: Two RNA binding proteins that deliver message from the 3¢ end. Gastroenterology 136(5):1495-1498.
4. Atasoy U, Watson J, Patel D, Keene JD. 1998. ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is upregulated during serum stimulation and T cell activation. J Cell Sci 111 (Pt 21):3145-3156.
5. Bai D, Gao Q, Li C, Ge L, Gao Y, Wang H. 2012. A conserved TGFbeta1/HuR feedback circuit regulates the fibrogenic response in fibroblasts. Cell Signal 24(7):1426-1432.
6. Balakathiresan NS, Bhattacharyya S, Gutti U, Long RP, Jozwik C, Huang W, Srivastava M, Pollard HB, Biswas R. 2009. Tristetraprolin regulates IL-8 mRNA stability in cystic fibrosis lung epithelial cells. Am J Physiol Lung Cell Mol Physiol 296(6):L1012-1018.
7. Baou M, Jewell A, Murphy JJ. 2009. TIS11 family proteins and their roles in posttranscriptional gene regulation. J Biomed Biotechnol 2009:634520.
8. Baou M, Norton JD, Murphy JJ. 2011. AU-rich RNA binding proteins in hematopoiesis and leukemogenesis. Blood 118(22): 5732-5740.
9. Barbisan F, Mazzucchelli R, Santinelli A, Lopez-Beltran A, Cheng L, Scarpelli M, Montorsi F, Montironi R. 2009. Overexpression of ELAV-like protein HuR is associated with increased COX-2 expression in atrophy, high-grade prostatic intraepithelial neoplasia, and incidental prostate cancer in cystoprostatectomies. Eur Urol 56(1):105-112.
10. Barreau C, Paillard L, Osborne HB. 2005. AU-rich elements and associated factors: Are there unifying principles? Nucleic Acids Res 33(22):7138-7150.
11. Bhadada SV, Goyal BR, Patel MM. 2011. Angiogenic targets for potential disorders. Fundam Clin Pharmacol 25(1):29-47.
12. Blackshear PJ. 2002. Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 30 (Pt 6):945-952.
13. Bourcier C, Griseri P, Grepin R, Bertolotto C, Mazure N, Pages G. 2011. Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells. Am J Physiol Cell Physiol 301(3):C609-C618.
14. Boutaud O, Dixon DA, Oates JA, Sawaoka H. 2003. Tristetraprolin binds to the COX-2 mRNA 3¢ untranslated region in cancer cells. Adv Exp Med Biol 525:157-160.
15. Brennan CM, Steitz JA. 2001. HuR and mRNA stability. Cell Mol Life Sci 58(2):266-277.
16. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. 2009. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res 69(12):5168-5176.
17. Brewer G. 1991. An A+ U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell Biol 11(5):2460-2466.
18. Briata P, Chen CY, Ramos A, Gherzi R. 2013. Functional and molecular insights into KSRP function in mRNA decay. Biochim Biophys Acta 1829(6-7):689-694.
19. Brooks SA, Blackshear PJ. 2013. Tristetraprolin (TTP): Interactions with mRNA and proteins, and current thoughts on mechanisms of action. Biochim Biophys Acta 1829(6-7):666-679.
20. Brosens LA, Keller JJ, Pohjola L, Haglund C, Morsink FH, Iacobuzio-Donahue C, Goggins M, Giardiello FM, Ristimaki A, Offerhaus GJ. 2008. Increased expression of cytoplasmic HuR in familial adenomatous polyposis. Cancer Biol Ther 7(3):424-427.
21. Bustin SA, Nie XF, Barnard RC, Kumar V, Pascall JC, Brown KD, Leigh IM, Williams NS, McKay IA. 1994. Cloning and characterization of ERF-1, a human member of the Tis11 family of early-response genes. DNA Cell Biol 13(5):449-459.
22. Cao H, Tuttle JS, Blackshear PJ. 2004. Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein. J Biol Chem 279(20):21489-21499.
23. Carballo E, Gilkeson GS, Blackshear PJ. 1997. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J Clin Invest 100(5): 986-995.
24. Carballo E, Lai WS, Blackshear PJ. 1998. Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science 281(5379):1001-1005.
25. Carballo E, Lai WS, Blackshear PJ. 2000. Evidence that tristetraprolin is a physiological regulator of granulocytemacrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95(6):1891-1899.
26. Carmeliet P. 2005. Angiogenesis in life, disease and medicine. Nature 438(7070):932-936.
27. Carrick DM, Blackshear PJ. 2007. Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys 462(2):278-285.
28. Carrick DM, Lai WS, Blackshear PJ. 2004. The tandem CCCH zinc finger protein tristetraprolin and its relevance to cytokine mRNA turnover and arthritis. Arthritis Res Ther 6(6):248-264.
29. Cha HJ, Lee HH, Chae SW, Cho WJ, Kim YM, Choi HJ, Choi DH, Jung SW, Min YJ, Lee BJ, Park SE, Park JW. 2011. Tristetraprolin downregulates the expression of both VEGF and COX-2 in human colon cancer. Hepatogastroenterology 58(107-108):790-795.
30. Chang YF, Imam JS, Wilkinson MF. 2007. The nonsensemediated decay RNA surveillance pathway. Annu Rev Biochem 76:51-74.
31. Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJ, Stoecklin G, Moroni C, Mann M, Karin M. 2001. AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 107(4):451-464.
32. Chen CY, Shyu AB. 1995. AU-rich elements: Characterization and importance in mRNA degradation. Trends Biochem Sci 20(11):465-470.
33. Chen YL, Huang YL, Lin NY, Chen HC, Chiu WC, Chang CJ. 2006. Differential regulation of ARE-mediated TNFalpha and IL-1beta mRNA stability by lipopolysaccharide in RAW264.7 cells. Biochem Biophys Res Commun 346(1):160-168.
34. Chrestensen CA, Schroeder MJ, Shabanowitz J, Hunt DF, Pelo JW, Worthington MT, Sturgill TW. 2004. MAPKAP kinase 2 phosphorylates tristetraprolin on in vivo sites including Ser178, a site required for 14-3-3 binding. J Biol Chem 279(11):10176-10184.
35. Chu WM. 2013. Tumor necrosis factor. Cancer Lett 328(2): 222-225.
36. Chung HJ, Liu J, Dundr M, Nie Z, Sanford S, Levens D. 2006. FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol 26(17):6584-6597.
37. Ciais D, Cherradi N, Bailly S, Grenier E, Berra E, Pouyssegur J, Lamarre J, Feige JJ. 2004. Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. Oncogene 23(53):8673-8680.
38. Ciais D, Cherradi N, Feige JJ. 2013. Multiple functions of tristetraprolin/TIS11 RNA-binding proteins in the regulation of mRNA biogenesis and degradation. Cell Mol Life Sci 70:2031-2043.
39. Datta S, Biswas R, Novotny M, Pavicic PG, Jr., Herjan T, Mandal P, Hamilton TA. 2008. Tristetraprolin regulates CXCL1 (KC) mRNA stability. J Immunol 180(4):2545-2552.
40. Datta S, Novotny M, Pavicic PG, Jr., Zhao C, Herjan T, Hartupee J, Hamilton T. 2010. IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. J Immunol 184(3):1484-1491.
41. Deleault KM, Skinner SJ, Brooks SA. 2008. Tristetraprolin regulates TNF TNF-alpha mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 45(1):13-24.
42. Derynck R, Akhurst RJ, Balmain A. 2001. TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29(2):117-129.
43. Di Marco S, Hel Z, Lachance C, Furneaux H, Radzioch D. 2001. Polymorphism in the 3¢-untranslated region of TNFalpha mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA. Nucleic Acids Res 29(4):863-871.
44. Dhamija S, Kuehne N, Winzen R, Doerrie A, Dittrich-Breiholz O, Thakur BK, Kracht M, Holtmann H. 2011. Interleukin-1 activates synthesis of interleukin-6 by interfering with a KH-type splicing regulatory protein (KSRP)-dependent translational silencing mechanism. J Biol Chem 286(38): 33279-33288.
45. Dixon DA, Tolley ND, King PH, Nabors LB, McIntyre TM, Zimmerman GA, Prescott SM. 2001. Altered expression of the mRNA stability factor HuR promotes cyclooxygenase-2 expression in colon cancer cells. J Clin Invest 108(11):1657-1665.
46. DuBois RN, McLane MW, Ryder K, Lau LF, Nathans D. 1990. A growth factor-inducible nuclear protein with a novel cysteine/histidine repetitive sequence. J Biol Chem 265(31): 19185-19191.
47. Eberhardt W, Doller A, Akool el S, Pfeilschifter J. 2007. Modulation of mRNA stability as a novel therapeutic approach. Pharmacol Ther 114(1):56-73.
48. Eberhardt W, Doller A, Pfeilschifter J. 2012. Regulation of the mRNA-binding protein HuR by posttranslational modification: Spotlight on phosphorylation. Curr Protein Pept Sci 13(4):380-390.
49. Eberle AB, Stalder L, Mathys H, Orozco RZ, Muhlemann O. 2008. Posttranscriptional gene regulation by spatial rearrangement of the 3¢ untranslated region. PLoS Biol 6(4):e92.
50. Essafi-Benkhadir K, Onesto C, Stebe E, Moroni C, Pages G. 2007. Tristetraprolin inhibits Ras-dependent tumor vascularization by inducing vascular endothelial growth factor mRNA degradation. Mol Biol Cell 18(11):4648-4658.
51. Fabregat I, Fernando J, Mainez J, Sancho P. 2013. TGF-beta signaling in cancer treatment. Curr Pharm Des. [Epub ahead of print] PMID 23944366.
52. Fan J, Ishmael FT, Fang X, Myers A, Cheadle C, Huang SK, Atasoy U, Gorospe M, Stellato C. 2011. Chemokine transcripts as targets of the RNA-binding protein HuR in human airway epithelium. J Immunol 186(4):2482-2494.
53. Fan XC, Steitz JA. 1998. Overexpression of HuR, a nuclearcytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J 17(12):3448-3460.
54. Ferrara N. 2010. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21(1):21-26.
55. Ford LP, Watson J, Keene JD, Wilusz J. 1999. ELAV proteins stabilize deadenylated intermediates in a novel in vitro mRNA deadenylation/degradation system. Genes Dev 13(2):188-201.
56. Gaba A, Grivennikov SI, Do MV, Stumpo DJ, Blackshear PJ, Karin M. 2012. Cutting edge: IL-10-mediated tristetraprolin induction is part of a feedback loop that controls macrophage STAT3 activation and cytokine production. J Immunol 189(5):2089-2093.
57. Galbiati V, Carne A, Mitjans M, Galli CL, Marinovich M, Corsini E. 2012. Isoeugenol destabilizes IL-8 mRNA expression in THP-1 cells through induction of the negative regulator of mRNA stability tristetraprolin. Arch Toxicol 86(2):239-248.
58. Gherzi R, Lee KY, Briata P, Wegmuller D, Moroni C, Karin M, Chen CY. 2004. A KH domain RNA binding protein, KSRP, promotes ARE-directed mRNA turnover by recruiting the degradation machinery. Mol Cell 14(5):571-583.
59. Gratacos FM, Brewer G. 2010. The role of AUF1 in regulated mRNA decay. Wiley Interdiscip Rev RNA 1(3):457-473.
60. Griseri P, Bourcier C, Hieblot C, Essafi-Benkhadir K, Chamorey E, Touriol C, Pages G. 2011. A synonymous polymorphism of the Tristetraprolin (TTP) gene, an AU-rich mRNA-binding protein, affects translation efficiency and response to Herceptin treatment in breast cancer patients. Hum Mol Genet 20(23):4556-4568.
61. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL. 2011. AREsite: A database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res 39 (Database issue): D66-D69.
62. Guo Y, Xu F, Lu T, Duan Z, Zhang Z. 2012. Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904-910.
63. Gutschalk CM, Herold-Mende CC, Fusenig NE, Mueller MM. 2006. Granulocyte colony-stimulating factor and granulocytemacrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo. Cancer Res 66(16):8026-8036.
64. Haaland CM, Heaphy CM, Butler KS, Fischer EG, Griffith JK, Bisoffi M. 2009. Differential gene expression in tumor adjacent histologically normal prostatic tissue indicates field cancerization. Int J Oncol 35(3):537-546.
65. Halbeisen RE, Galgano A, Scherrer T, Gerber AP. 2008. Posttranscriptional gene regulation: From genome-wide studies to principles. Cell Mol Life Sci 65(5):798-813.
66. Halees AS, El-Badrawi R, Khabar KS. 2008. ARED organism: Expansion of ARED reveals AU-rich element cluster variations between human and mouse. Nucleic Acids Res 36 (Database issue):D137-D140.
67. Hamilton T, Li X, Novotny M, Pavicic PG, Jr., Datta S, Zhao C, Hartupee J, Sun D. 2012. Cell type-and stimulusspecific mechanisms for post-transcriptional control of neutrophil chemokine gene expression. J Leukoc Biol 91(3): 377-383.
68. Hamilton T, Novotny M, Pavicic PJ, Jr., Herjan T, Hartupee J, Sun D, Zhao C, Datta S. 2010. Diversity in post-transcriptional control of neutrophil chemoattractant cytokine gene expression. Cytokine 52(1-2):116-122.
69. Hao S, Baltimore D. 2009. The stability of mRNA influences the temporal order of the induction of genes encoding inflammatory molecules. Nat Immunol 10(3):281-288.
70. Heinonen M, Hemmes A, Salmenkivi K, Abdelmohsen K, Vilen ST, Laakso M, Leidenius M, Salo T, Hautaniemi S, Gorospe M, Heikkila P, Haglund C, Ristimaki A. 2011. Role of RNA binding protein HuR in ductal carcinoma in situ of the breast. J Pathol 224(4):529-539.
71. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, Gaestel M. 2006. Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 26(6):2399-2407.
72. Hutin S, Lee Y, Glaunsinger BA. 2013. An RNA element in human interleukin 6 confers escape from degradation by the gammaherpesvirus SOX protein. J Virol 87(8):4672-4682.
73. Ido K, Nakagawa T, Sakuma T, Takeuchi H, Sato K, Kubota T. 2008. Expression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumors. Neuropathology 28(6):604-611.
74. Ino T, Yasui H, Hirano M, Kurosawa Y. 1995. Identification of a member of the TIS11 early response gene family at the insertion point of a DNA fragment containing a gene for the T-cell receptor beta chain in an acute T-cell leukemia. Oncogene 11(12):2705-2710.
75. Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, Moilanen E. 2006. Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3alpha synthesis in activated macrophages. Mediators Inflamm 2006(6):40691.
76. Johnson BA, Geha M, Blackwell TK. 2000. Similar but distinct effects of the tristetraprolin/TIS11 immediate-early proteins on cell survival. Oncogene 19(13):1657-1664.
77. Kedde M, Agami R. 2008. Interplay between microRNAs and RNA-binding proteins determines developmental processes. Cell Cycle 7(7):899-903.
78. Khabar KS. 2010. Post-transcriptional control during chronic inflammation and cancer: A focus on AU-rich elements. Cell Mol Life Sci 67(17):2937-2955.
79. Khaleghpour K, Svitkin YV, Craig AW, DeMaria CT, Deo RC, Burley SK, Sonenberg N. 2001. Translational repression by a novel partner of human poly(A) binding protein, Paip2. Mol Cell 7(1):205-216.
80. Kim TW, Yim S, Choi BJ, Jang Y, Lee JJ, Sohn BH, Yoo HS, Yeom YI, Park KC. 2010. Tristetraprolin regulates the stability of HIF-1alpha mRNA during prolonged hypoxia. Biochem Biophys Res Commun 391(1):963-968.
81. King EM, Kaur M, Gong W, Rider CF, Holden NS, Newton R. 2009. Regulation of tristetraprolin expression by interleukin-1 beta and dexamethasone in human pulmonary epithelial cells: Roles for nuclear factor-kappa B and p38 mitogen-activated protein kinase. J Pharmacol Exp Ther 330(2):575-585.
82. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, Blackshear PJ. 1999. Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19(6):4311-4323.
83. Lai WS, Kennington EA, Blackshear PJ. 2003. Tristetraprolin and its family members can promote the cell-free deadenylation of AU-rich element-containing mRNAs by poly(A) ribonuclease. Mol Cell Biol 23(11):3798-3812.
84. Lai WS, Parker JS, Grissom SF, Stumpo DJ, Blackshear PJ. 2006. Novel mRNA targets for tristetraprolin (TTP) identified by global analysis of stabilized transcripts in TTP-deficient fibroblasts. Mol Cell Biol 26(24):9196-9208.
85. Lai WS, Stumpo DJ, Blackshear PJ. 1990. Rapid insulinstimulated accumulation of an mRNA encoding a prolinerich protein. J Biol Chem 265(27):16556-16563.
86. Lauriola L, Granone P, Ramella S, Lanza P, Ranelletti FO. 2012. Expression of the RNA-binding protein HuR and its clinical significance in human stage I and II lung adenocarcinoma. Histol Histopathol 27(5):617-626.
87. Le Quesne J. 2013. UTRly malignant: mRNA stability and the invasive phenotype in breast cancer. J Pathol 230(2):129-131.
88. Lee HH, Son YJ, Lee WH, Park YW, Chae SW, Cho WJ, Kim YM, Choi HJ, Choi DH, Jung SW, Min YJ, Park SE, Lee BJ, Cha HJ, Park JW. 2010. Tristetraprolin regulates expression of VEGF and tumorigenesis in human colon cancer. Int J Cancer 126(8):1817-1827.
89. Lee HH, Yoon NA, Vo MT, Kim CW, Woo JM, Cha HJ, Cho YW, Lee BJ, Cho WJ, Park JW. 2012. Tristetraprolin downregulates IL-17 through mRNA destabilization. FEBS Lett 586(1):41-46.
90. Levy NS, Chung S, Furneaux H, Levy AP. 1998. Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J Biol Chem 273:6417-6423.
91. Liekens S, De Clercq E, Neyts J. 2001. Angiogenesis: Regulators and clinical applications. Biochem Pharmacol 61(3): 253-270.
92. Liu Y, Han ZP, Zhang SS, Jing YY, Bu XX, Wang CY, Sun K, Jiang GC, Zhao X, Li R, Gao L, Zhao QD, Wu MC, Wei LX. 2011. Effects of inflammatory factors on mesenchymal stem cells and their role in the promotion of tumor angiogenesis in colon cancer. J Biol Chem 286(28):25007-25015.
93. Lu JY, Sadri N, Schneider RJ. 2006. Endotoxic shock in AUF1 knockout mice mediated by failure to degrade proinflammatory cytokine mRNAs. Genes Dev 20(22):3174-3184.
94. Ma WJ, Cheng S, Campbell C, Wright A, Furneaux H. 1996. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J Biol Chem 271(14):8144-8151.
95. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, Clark AR. 2001. Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 21(19):6461-6469.
96. Mangus DA, Evans MC, Jacobson A. 2003. Poly(A)-binding proteins: Multifunctional scaffolds for the post-transcriptional control of gene expression. Genome Biol 4(7):223.
97. Mann A, Breuhahn K, Schirmacher P, Blessing M. 2001. Keratinocyte-derived granulocyte-macrophage colony stimulating factor accelerates wound healing: Stimulation of keratinocyte proliferation, granulation tissue formation, and vascularization. J Invest Dermatol 117(6):1382-1390.
98. Meisner NC, Hackermuller J, Uhl V, Aszodi A, Jaritz M, Auer M. 2004. mRNA openers and closers: Modulating AU-rich element-controlled mRNA stability by a molecular switch in mRNA secondary structure. Chembiochem 5(10):1432-1447.
99. Metcalf D. 2010. The colony-stimulating factors and cancer. Nat Rev Cancer 10(6):425-434.
100. Milke L, Schulz K, Weigert A, Sha W, Schmid T, Brune B. 2013. Depletion of tristetraprolin in breast cancer cells increases interleukin-16 expression and promotes tumor infiltration with monocytes/macrophages. Carcinogenesis 34(4): 850-857.
101. Mueller MM, Fusenig NE. 2004. Friends or foes-bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4(11): 839-849.
102. Nabors LB, Gillespie GY, Harkins L, King PH. 2001. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine-and uridine-rich elements within the 3¢ untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 61(5):2154-2161.
103. Nabors LB, Suswam E, Huang Y, Yang X, Johnson MJ, King PH. 2003. Tumor necrosis factor alpha induces angiogenic factor up-regulation in malignant glioma cells: A role for RNA stabilization and HuR. Cancer Res 63(14):4181-4187.
104. Niesporek S, Kristiansen G, Thoma A, Weichert W, Noske A, Buckendahl AC, Jung K, Stephan C, Dietel M, Denkert C. 2008. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. Int J Oncol 32(2):341-347.
105. Ogami K, Yamaguchi R, Imoto S, Tamada Y, Araki H, Print C, Miyano S. 2012. Computational gene network analysis reveals TNF-induced angiogenesis. BMC Syst Biol 6 (Suppl 2):S12.
106. Ogawa K, Chen F, Kim YJ, Chen Y. 2003. Transcriptional regulation of tristetraprolin by transforming growth factorbeta in human T cells. J Biol Chem 278(32):30373-30381.
107. Ogilvie RL, Abelson M, Hau HH, Vlasova I, Blackshear PJ, Bohjanen PR. 2005. Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J Immunol 174(2):953-961.
108. Onesto C, Berra E, Grepin R, Pages G. 2004. Poly(A)-binding protein-interacting protein 2, a strong regulator of vascular endothelial growth factor mRNA. J Biol Chem 279(33): 34217-34226.
109. Onesto C, Hannoun-Levi JM, Chamorey E, Formento JL, Ramaioli A, Pages G. 2006. Vascular endothelial growth factor-A and Poly(A) binding protein-interacting protein 2 expression in human head and neck carcinomas: Correlation and prognostic significance. Br J Cancer 94(10):1516-1523.
110. Phillips K, Kedersha N, Shen L, Blackshear PJ, Anderson P. 2004. Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor alpha, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci USA 101(7):2011-2016.
111. Planel S, Salomon A, Jalinot P, Feige JJ, Cherradi N. 2010. A novel concept in antiangiogenic and antitumoral therapy: Multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1. Oncogene 29(45):5989-6003.
112. Polacek C, Friebe P, Harris E. 2009. Poly(A)-binding protein binds to the non-polyadenylated 3¢ untranslated region of dengue virus and modulates translation efficiency. J Gen Virol 90 (Pt 3):687-692.
113. Rabani M, Kertesz M, Segal E. 2008. Computational prediction of RNA structural motifs involved in posttranscriptional regulatory processes. Proc Natl Acad Sci USA 105(39): 14885-14890.
114. Raghavan A, Robison RL, McNabb J, Miller CR, Williams DA, Bohjanen PR. 2001. HuA and tristetraprolin are induced following T cell activation and display distinct but overlapping RNA binding specificities. J Biol Chem 276(51): 47958-47965.
115. Raineri I, Wegmueller D, Gross B, Certa U, Moroni C. 2004. Roles of AUF1 isoforms, HuR and BRF1 in ARE-dependent mRNA turnover studied by RNA interference. Nucleic Acids Res 32(4):1279-1288.
116. Rosenfeld AB. 2011. Suppression of cellular transformation by poly (A) binding protein interacting protein 2 (Paip2). PLoS One 6(9):e25116.
117. Ross CR, Brennan-Laun SE, Wilson GM. 2012. Tristetraprolin: Roles in cancer and senescence. Ageing Res Rev 11(4):473-484.
118. Rounbehler RJ, Fallahi M, Yang C, Steeves MA, Li W, Doherty JR, Schaub FX, Sanduja S, Dixon DA, Blackshear PJ, Cleveland JL. 2012. Tristetraprolin impairs myc-induced lymphoma and abolishes the malignant state. Cell 150(3): 563-574.
119. Sachidanandan C, Sambasivan R, Dhawan J. 2002. Tristetraprolin and LPS-inducible CXC chemokine are rapidly induced in presumptive satellite cells in response to skeletal muscle injury. J Cell Sci 115 (Pt 13):2701-2712.
120. Sandler H, Stoecklin G. 2008. Control of mRNA decay by phosphorylation of tristetraprolin. Biochem Soc Trans 36 (Pt 3):491-496.
121. Sanduja S, Blanco FF, Young LE, Kaza V, Dixon DA. 2012. The role of tristetraprolin in cancer and inflammation. Front Biosci 17:174-188.
122. Sanduja S, Kaza V, Dixon DA. 2009. The mRNA decay factor tristetraprolin (TTP) induces senescence in human papillomavirus-transformed cervical cancer cells by targeting E6-AP ubiquitin ligase. Aging (Albany NY) 1(9):803-817.
123. Sansone P, Bromberg J. 2012. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol 30(9): 1005-1014.
124. Seko Y, Cole S, Kasprzak W, Shapiro BA, Ragheb JA. 2006. The role of cytokine mRNA stability in the pathogenesis of autoimmune disease. Autoimmun Rev 5(5):299-305.
125. Seoane J. 2006. Escaping from the TGFbeta anti-proliferative control. Carcinogenesis 27(11):2148-2156.
126. Shang Y, Doan CN, Arnold TD, Lee S, Tang AA, Reichardt LF, Huang EJ. 2013. Transcriptional corepressors HIPK1 and HIPK2 control angiogenesis via TGF-beta-TAK1-dependent mechanism. PLoS Biol 11(4):e1001527.
127. Shi JX, Su X, Xu J, Zhang WY, Shi Y. 2012. HuR post-transcriptionally regulates TNF-alpha-induced IL-6 expression in human pulmonary microvascular endothelial cells mainly via tristetraprolin. Respir Physiol Neurobiol 181(2):154-161.
128. Shih SC, Claffey KP. 1999. Regulation of human vascular endothelial growth factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J Biol Chem 274(3):1359-1365.
129. Sohn BH, Park IY, Lee JJ, Yang SJ, Jang YJ, Park KC, Kim DJ, Lee DC, Sohn HA, Kim TW, Yoo HS, Choi JY, Bae YS, Yeom YI. 2010. Functional switching of TGF-beta1 signaling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 138(5):1898-1908.
130. Spooren A, Mestdagh P, Rondou P, Kolmus K, Haegeman G, Gerlo S. 2011. IL-1beta potently stabilizes IL-6 mRNA in human astrocytes. Biochem Pharmacol 81(8):1004-1015.
131. Srikantan S, Gorospe M. 2012. HuR function in disease. Front Biosci 17:189-205.
132. Stoecklin G, Ming XF, Looser R, Moroni C. 2000. Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol 20(11):3753-3763.
133. Stoecklin G, Tenenbaum SA, Mayo T, Chittur SV, George AD, Baroni TE, Blackshear PJ, Anderson P. 2008. Genome-wide analysis identifies interleukin-10 mRNA as target of tristetraprolin. J Biol Chem 283(17):11689-11699.
134. Sun L, Stoecklin G, Van Way S, Hinkovska-Galcheva V, Guo RF, Anderson P, Shanley TP. 2007. Tristetraprolin (TTP)-14-3-3 complex formation protects TTP from dephosphorylation by protein phosphatase 2a and stabilizes tumor necrosis factor-alpha mRNA. J Biol Chem 282(6):3766-3777.
135. Suswam E, Li Y, Zhang X, Gillespie GY, Li X, Shacka JJ, Lu L, Zheng L, King PH. 2008. Tristetraprolin down-regulates interleukin-8 and vascular endothelial growth factor in malignant glioma cells. Cancer Res 68(3):674-682.
136. Suswam EA, Nabors LB, Huang Y, Yang X, King PH. 2005. IL-1beta induces stabilization of IL-8 mRNA in malignant breast cancer cells via the 3¢ untranslated region: Involvement of divergent RNA-binding factors HuR, KSRP and TIAR. Int J Cancer 113(6):911-919.
137. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, Blackshear PJ. 1996a. A pathogenetic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4(5):445-454.
138. Taylor GA, Lai WS, Oakey RJ, Seldin MF, Shows TB, Eddy RL, Jr., Blackshear PJ. 1991. The human TTP protein: Sequence, alignment with related proteins, and chromosomal localization of the mouse and human genes. Nucleic Acids Res 19(12):3454.
139. Taylor GA, Thompson MJ, Lai WS, Blackshear PJ. 1996b. Mitogens stimulate the rapid nuclear to cytosolic translocation of tristetraprolin, a potential zinc-finger transcription factor. Mol Endocrinol 10(2):140-146.
140. Tiedje C, Ronkina N, Tehrani M, Dhamija S, Laass K, Holtmann H, Kotlyarov A, Gaestel M. 2012. The p38/MK2-driven exchange between tristetraprolin and HuR regulates AU-rich element-dependent translation. PLoS Genet 8(9): e1002977.
141. Upadhyay R, Sanduja S, Kaza V, Dixon DA. 2013. Genetic polymorphisms in RNA binding proteins contribute to breast cancer survival. Int J Cancer 132(3):E128-E138.
142. Van Tubergen E, Vander Broek R, Lee J, Wolf G, Carey T, Bradford C, Prince M, Kirkwood KL, D'Silva NJ. 2011. Tristetraprolin regulates interleukin-6, which is correlated with tumor progression in patients with head and neck squamous cell carcinoma. Cancer 117(12):2677-2689.
143. Van Tubergen EA, Banerjee R, Liu M, Vander Broek R, Light E, Kuo S, Feinberg SE, Willis AL, Wolf G, Carey T, Bradford C, Prince M, Worden FP, Kirkwood KL, D'Silva NJ. 2013. Inactivation or loss of TTP promotes invasion in head and neck cancer via transcript stabilization and secretion of MMP9, MMP2, and IL-6. Clin Cancer Res 19(5):1169-1179.
144. Voronov E, Carmi Y, Apte RN. 2007. Role of IL-1-mediated inflammation in tumor angiogenesis. Adv Exp Med Biol 601:265-270.
145. Wagner BJ, DeMaria CT, Sun Y, Wilson GM, Brewer G. 1998. Structure and genomic organization of the human AUF1 gene: Alternative pre-mRNA splicing generates four protein isoforms. Genomics 48(2):195-202.
146. Wajant H, Pfizenmaier K, Scheurich P. 2003. Tumor necrosis factor signaling. Cell Death Differ 10(1):45-65.
147. Wang X, Abraham S, McKenzie JA, Jeffs N, Swire M, Tripathi VB, Luhmann UF, Lange CA, Zhai Z, Arthur HM, Bainbridge JW, Moss SE, Greenwood J. 2013. LRG1 promotes angiogenesis by modulating endothelial TGF-beta signalling. Nature 499(7458):306-311.
148. White EJ, Brewer G, Wilson GM. 2013. Post-transcriptional control of gene expression by AUF1: Mechanisms, physiological targets, and regulation. Biochim Biophys Acta 1829(6-7):680-688.
149. Winzen R, Thakur BK, Dittrich-Breiholz O, Shah M, Redich N, Dhamija S, Kracht M, Holtmann H. 2007. Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets. Mol Cell Biol 27(23):8388-8400.
150. Xin H, Brown JA, Gong C, Fan H, Brewer G, Gnarra JR. 2012. Association of the von Hippel-Lindau protein with AUF1 and posttranscriptional regulation of VEGFA mRNA. Mol Cancer Res 10(1):108-120.
151. Young LE, Sanduja S, Bemis-Standoli K, Pena EA, Price RL, Dixon DA. 2009. The mRNA binding proteins HuR and tristetraprolin regulate cyclooxygenase 2 expression during colon carcinogenesis. Gastroenterology 136(5):1669-1679.
152. Yuan Z, Sanders AJ, Ye L, Jiang WG. 2010. HuR, a key posttranscriptional regulator, and its implication in progression of breast cancer. Histol Histopathol 25(10):1331-1340.
153. Yuan Z, Sanders AJ, Ye L, Wang Y, Jiang WG. 2011. Prognostic value of the human antigen R (HuR) in human breast cancer: High level predicts a favourable prognosis. Anticancer Res 31(1):303-310.
154. Zhang W, Wagner BJ, Ehrenman K, Schaefer AW, DeMaria CT, Crater D, DeHaven K, Long L, Brewer G. 1993. Purification, characterization, and cDNA cloning of an AU-rich element RNA-binding protein, AUF1. Mol Cell Biol 13(12): 7652-7665.
155. Zhao W, Liu M, D'Silva NJ, Kirkwood KL. 2011. Tristetraprolin regulates interleukin-6 expression through p38 MAPK-dependent affinity changes with mRNA 3¢ untranslated region. J Interferon Cytokine Res 31(8):629-637.
156. Zhu Z, Wang B, Bi J, Zhang C, Guo Y, Chu H, Liang X, Zhong C, Wang J. 2013. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumour Biol 34(4):2299-2308.
157. Zucconi BE, Wilson GM. 2011. Modulation of neoplastic gene regulatory pathways by the RNA-binding factor AUF1. Front Biosci 16:2307-2325.